Literature DB >> 11883957

Deficiency of alpha-dystroglycan in muscle-eye-brain disease.

Hiroki Kano1, Kazuhiro Kobayashi, Ralf Herrmann, Masaji Tachikawa, Hiroshi Manya, Ichizo Nishino, Ikuya Nonaka, Volker Straub, Beril Talim, Thomas Voit, Haluk Topaloglu, Tamao Endo, Hideki Yoshikawa, Tatsushi Toda.   

Abstract

Alpha-dystroglycan is a component of the dystrophin-glycoprotein-complex, which is the major mechanism of attachment between the cytoskeleton and the extracellular matrix. Muscle-eye-brain disease (MEB) is an autosomal recessive disorder characterized by congenital muscular dystrophy, ocular abnormalities and lissencephaly. We recently found that MEB is caused by mutations in the protein O-linked mannose beta1,2-N-acetylglucosaminyltransferase (POMGnT1) gene. POMGnT1 is a glycosylation enzyme that participates in the synthesis of O-mannosyl glycan, a modification that is rare in mammals but is known to be a laminin-binding ligand of alpha-dystroglycan. Here we report a selective deficiency of alpha-dystroglycan in MEB patients. This finding suggests that alpha-dystroglycan is a potential target of POMGnT1 and that altered glycosylation of alpha-dystroglycan may play a critical role in the pathomechanism of MEB and some forms of muscular dystrophy. (C)2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11883957     DOI: 10.1006/bbrc.2002.6608

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  28 in total

Review 1.  The Finnish Disease Heritage III: the individual diseases.

Authors:  Reijo Norio
Journal:  Hum Genet       Date:  2003-03-08       Impact factor: 4.132

2.  Differential glycosylation of α-dystroglycan and proteins other than α-dystroglycan by like-glycosyltransferase.

Authors:  Peng Zhang; Huaiyu Hu
Journal:  Glycobiology       Date:  2011-09-19       Impact factor: 4.313

3.  RPTPζ/phosphacan is abnormally glycosylated in a model of muscle-eye-brain disease lacking functional POMGnT1.

Authors:  C A Dwyer; E Baker; H Hu; R T Matthews
Journal:  Neuroscience       Date:  2012-06-19       Impact factor: 3.590

Review 4.  The genetic and molecular basis of muscular dystrophy: roles of cell-matrix linkage in the pathogenesis.

Authors:  Motoi Kanagawa; Tatsushi Toda
Journal:  J Hum Genet       Date:  2006-09-13       Impact factor: 3.172

5.  Muscular dystrophy associated with alpha-dystroglycan deficiency in Sphynx and Devon Rex cats.

Authors:  Paul T Martin; G Diane Shelton; Peter J Dickinson; Beverly K Sturges; Rui Xu; Richard A LeCouteur; Ling T Guo; Robert A Grahn; Harriet P Lo; Kathryn N North; Richard Malik; Eva Engvall; Leslie A Lyons
Journal:  Neuromuscul Disord       Date:  2008-11-05       Impact factor: 4.296

6.  Biochemical and biophysical changes underlie the mechanisms of basement membrane disruptions in a mouse model of dystroglycanopathy.

Authors:  Peng Zhang; Yuan Yang; Joseph Candiello; Trista L Thorn; Noel Gray; Willi M Halfter; Huaiyu Hu
Journal:  Matrix Biol       Date:  2013-02-27       Impact factor: 11.583

7.  Retinal ectopias and mechanically weakened basement membrane in a mouse model of muscle-eye-brain (MEB) disease congenital muscular dystrophy.

Authors:  Huaiyu Hu; Joseph Candiello; Peng Zhang; Sherry L Ball; David A Cameron; Willi Halfter
Journal:  Mol Vis       Date:  2010-07-28       Impact factor: 2.367

Review 8.  Developmental genetic malformations of the cerebral cortex.

Authors:  Volney L Sheen; Christopher A Walsh
Journal:  Curr Neurol Neurosci Rep       Date:  2003-09       Impact factor: 5.081

9.  Komrower Lecture. Congenital disorders of glycosylation (CDG): it's all in it!

Authors:  J Jaeken
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

10.  Adeno-associated viral-mediated LARGE gene therapy rescues the muscular dystrophic phenotype in mouse models of dystroglycanopathy.

Authors:  Miao Yu; Yonglin He; Kejian Wang; Peng Zhang; Shengle Zhang; Huaiyu Hu
Journal:  Hum Gene Ther       Date:  2013-03       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.